# Mark Lebwohl

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/mark-lebwohl/

## Facts

| Field | Value |
| --- | --- |
| Citations | 56,799 |
| Field | Psoriasis: Treatment and Pathogenesis |
| h-index | 120 |
| i10-index | 555 |
| Last Known Institution | Mount Sinai Hospital |
| OpenAlex ID | https://openalex.org/A5038505651 |
| ORCID iD | https://orcid.org/0000-0002-4705-5303 |
| Works | 1,406 |

## Researcher papers

Showing 12 of 13.

- [Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)](https://scholariq.org/papers/efficacy-and-safety-of-ustekinumab-a-human-interleukin-12-23-monoclonal-antibody-2/)
- [Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics](https://scholariq.org/papers/joint-aad-npf-guidelines-of-care-for-the-management-and-treatment-of-psoriasis/)
- [Psoriasis](https://scholariq.org/papers/psoriasis/)
- [Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis](https://scholariq.org/papers/phase-3-studies-comparing-brodalumab-with-ustekinumab-in-psoriasis/)
- [Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials](https://scholariq.org/papers/efficacy-and-safety-of-risankizumab-in-moderate-to-severe-plaque-psoriasis/)
- [Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults](https://scholariq.org/papers/efficacy-and-safety-of-crisaborole-ointment-a-novel-nonsteroidal/)
- [Guidelines of care for the management of psoriasis and psoriatic arthritis](https://scholariq.org/papers/guidelines-of-care-for-the-management-of-psoriasis-and-psoriatic-arthritis/)
- [Patient perspectives in the management of psoriasis: Results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey](https://scholariq.org/papers/patient-perspectives-in-the-management-of-psoriasis-results-from-the-population/)
- [Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities](https://scholariq.org/papers/joint-aad-npf-guidelines-of-care-for-the-management-and-treatment-of-psoriasis-2/)
- [Bimekizumab versus Secukinumab in Plaque Psoriasis](https://scholariq.org/papers/bimekizumab-versus-secukinumab-in-plaque-psoriasis/)
- [Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up](https://scholariq.org/papers/long-term-safety-of-ustekinumab-in-patients-with-moderate-to-severe-psoriasis/)
- [Joint American Academy of Dermatology–National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies](https://scholariq.org/papers/joint-american-academy-of-dermatology-national-psoriasis-foundation-guidelines/)

## Researcher topics

- [Psoriasis: Treatment and Pathogenesis](https://scholariq.org/topics/psoriasis-treatment-and-pathogenesis/)
- [Dermatology and Skin Diseases](https://scholariq.org/topics/dermatology-and-skin-diseases/)
- [Spondyloarthritis Studies and Treatments](https://scholariq.org/topics/spondyloarthritis-studies-and-treatments/)
- [Autoimmune Bullous Skin Diseases](https://scholariq.org/topics/autoimmune-bullous-skin-diseases/)
- [Pharmaceutical studies and practices](https://scholariq.org/topics/pharmaceutical-studies-and-practices/)

## Researcher university

- [Mount Sinai Hospital](https://scholariq.org/institutions/mount-sinai-hospital-4/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.